Convergent Therapeutics Appoints Barbara Duncan to Board of Directors
News & media
Convergent Therapeutics Announces First Shipments of Actinium 225 from Cardinal Health to Support the CONVERGE-01 Phase 2 Clinical Trial
Convergent Therapeutics Announces First Patient Treated in Phase II Clinical Trial with Lead Therapeutic Candidate and Corporate Updates
Convergent Therapeutics Announces FDA Clearance of IND Application for CONV01-α, a Best-in-Class Radioantibody Targeting Prostate-Specific Membrane Antigen
Convergent Therapeutics Appoints Scott Myers as Chairman of its Board of Directors
Convergent Therapeutics Expands Leadership Team with the Appointments of Neil Bander, MD. as Chief Scientific Officer, Eric M. Sullivan as Chief Financial Officer, and Dimitris Voliotis, MD. as Senior Vice President of Clinical Development
Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Society of Clinical Oncology (ASCO) Annual Meeting 2023
Convergent raises $90M to develop its radiopharmaceutical for prostate cancer
Radioantibody startup led by prostate cancer experts raises $90M
Radiopharmaceutical company Convergent closes series A to the tune of $90M
Cambridge biotech raises $90 million for drug that uses radioactive atoms to fight prostate cancer
Six-person Cornell spinout raises $90M for prostate cancer drugs
May 3 Quick Takes: Clinical-stage targeted radio-antibody newco Convergent raises $90M A round
Convergent Therapeutics Announces $90 Million Series A Financing to Advance the Clinical Development of Radiopharmaceuticals for the Treatment of Prostate Cancer and Other Solid Tumors
Convergent Therapeutics Announces Updates on its Lead Therapeutic Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
Convergent Therapeutics to Announce Clinical Trial Updates on its Lead Candidate at the American Association for Cancer Research (AACR) Annual Meeting 2023
Dr. Bander on Preliminary Data on 225Ac-J591 Plus Pembrolizumab in mCRPC
Convergent Therapeutics Announces Presentations at the 2023 ASCO Genitourinary (GU) Cancers Symposium on its Lead Candidate
Convergent Therapeutics, Inc. Next Generation Radiopharmaceutical Therapies for Prostate – Philip Kantoff
Developing Next-Generation Radiopharmaceuticals
ESMO 2022: Advances in the Treatment of Cancer
The Future of Radiopharmaceuticals in the Treatment of Prostate Cancer – Philip Kantoff
Radioligands Advance Radiotherapy Premise With Greater Precision
Philip Kantoff: Next Generation Radiopharmaceutical Drug Development
Convergent Therapeutics — Next Generation Radiopharmaceutical Therapies for Cancer
Convergent Therapeutics Banking on Radioantibody Approach for PSMA-Targeted mCRPC Treatment
Interview with Convergent Therapeutics CEO Dr. Phil Kantoff
The Coming Wave Of Radio(bio)pharmaceuticals
Radiopharmaceutical Technology Creates Novel Radioantibodies to Treat Prostate Cancer with Dr. Phil Kantoff and Alex Brown — Convergent Therapeutics
Convergent Therapeutics and IONETIX Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
AACR: Philip Kantoff Discusses Convergent’s Unique Path to Treating Prostate Cancer
NorthStar Medical Radioisotopes and Convergent Therapeutics Announce Supply Agreement for Therapeutic Radioisotope Actinium-225 (Ac-225)
Dr. Philip Kantoff — Radiopharmaceutical cancer targeting with Convergent Therapeutics
Convergent Therapeutics and Point Biopharma Announce a Collaboration to Evaluate CONV01-α (Rosopatamab-225Ac) in combination with PNT2002 for Progressive Metastatic Castration-Resistant Prostate Cancer
Convergent Therapeutics Appoints Alexander Brown as Chief Operating Officer
Convergent Therapeutics Appoints Philip Kantoff, M.D. as Chief Executive Officer